RT Journal
A1 Coca S
T1 LIfe expectancy after treatment for systolic hypertension
JF JAMA
JO JAMA
YR 2012
FD April 4
VO 307
IS 13
SP 1368
OP 1369
DO 10.1001/jama.2012.389
UL http://dx.doi.org/10.1001/jama.2012.389
AB 
To the Editor: In the study by Dr Kostis and colleagues,1 the main outcome measures were cardiovascular death and all-cause mortality. After 22 years, approximately 60% of participants from the Systolic Hypertension in the Elderly Program (SHEP) trial died, and less than 50% of the deaths were from a cardiovascular cause. There were no statistically significant differences in all-cause mortality by the various techniques the investigators used in analyzing these data (area between active and placebo survival curves, log-rank test, time to 70th percentile survival). Instead, there were statistically significant differences between the intervention and control groups only for the outcome of cardiovascular death.